Antioxidant therapy in neurologic disease

Archives of Neurology

Volumn 57, Issue 9, 2000, Pages 1265-1270

  Delanty, Norman ^a,b   Dichter, Marc A ^b  

^a BEAUMONT HOSPITAL   (Ireland)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CREATINE; MANGANESE SUPEROXIDE DISMUTASE; MELATONIN; PYRROLOPYRIMIDINE DERIVATIVE; TIRILAZAD; UBIDECARENONE; URIC ACID;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEMENTIA; EPILEPSY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUNTINGTON CHOREA; MULTICENTER STUDY; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STROKE; SUBARACHNOID HEMORRHAGE;

EID: 0033824630     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.9.1265     Document Type: Review

References (71)

1. Oxidants, antioxidants, and the degenerative diseases of aging
2. Free radicals, antioxidants, and human disease: Curiosity, cause, or consequence?
3. Human disease, free radicals, and the oxidant/antioxidant balance
4. Oxygen radicals and human disease
5. Oxidative processes and antioxidative defense mechanisms in the aging brain
6. Antioxidant defense of the brain: A role for astrocytes
7. Oxidative damage in neurodegenerative disease
8. Aging, energy, and oxidative stress in neurodegenerative disease
9. Oxidative injury in the nervous system
10. Superior neuroprotective efficacy of a novel antioxidant (U-101033E) with improved blood-brain barrier permeability in focal cerebral ischemia
11. Neuroprotective effects of the novel brain-penetrating pyrrolopyrimidine antioxidants U-101033E and U-104067F against post-ischemic degeneration of nigrostriatal neurons
12. 10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects
13. Protection and recycling of α-tocopherol in human erythrocytes by intracellular ascorbic acid
14. Vitamin C supplementation restores the impaired vitamin E status of guinea pigs fed oxidized frying oil
15. Antioxidants and dementia
16. Safety and tolerability of the antioxidant 0P6-14117 in HIV-associated cognitive impairment
17. 2-induced lipid peroxidation in rat amygdala
18. Comparison of the effects of ascorbyl γ-linolenic acid and γ-linolenic acid in the correction of neurovascular deficits in diabetic rats
19. Antioxidant effect of flavonoids
20. Lycopene: Antioxidant and biological effects and its bioavailability in the human
21. Safety of antioxidant vitamins
22. Effect of vitamin E on the anticoagulant response to warfarin
23. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers
24. Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats
25. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: Suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction
26. 10 administration prevents the development of ischemic brain lesions in a rabbit model of symptomatic vasospasm
27. Antioxidant, 0P6-14117, attenuates edema formation and behavioral deficits following cortical contusion in rats
28. Pyrrolopyrimidines: Novel brainpenetrating antioxiodants with neuroprotective activity in brain injury and ischemia models
29. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis
30. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrate Implications for the treatment of multiple sclerosis
31. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease
32. Effects of the sulphydryl donor N-acetyl-L-cysteine on nerve conduction, perfusion, maturation and regeneration following freeze damage in diabetic rats
33. Melatonin reduces the increase in 8-hydroxy-deoxyguanosine levels in the brain and liver of kainic acid-treated rats
34. Seizures and hippocampal damage produced by dendrotoxin-K in rats is prevented by the 21-aminosteroid U-743896
35. Adenosines scavenged hydroxyl radicals and prevented posttraumatic epilepsy
36. Melatonin inhibits iron-induced epileptic discharges in rats by suppressing peroxidation
37. Antioxidant treatment protects striatal neurons against excitotoxic insults
38. Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant
39. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice
40. A series of prostaglandin F2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalysed mechanism
41. 8-epi-PCF(2α): Specific analysis of an isoeicosanoid as an index of oxidant stress in vivo
42. DNA oxidation matters: The HPLC-electrochemical detection assay of 8-oxo-deoxyguanosine and 8-oxo-guanine
43. Detection and quantititation of nitrotyrosine residues in proteins: In vivo markers of peroxynitrite
44. Can antioxidant vitamins materially reduce oxidative damage in humans?
45. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
46. The effect of deprenyl and levodopa on the progression of Parkinson's disease
47. Antioxidant mechanism and protection of nigral neurons against MPP(+) toxicity by deprenyl (selegiline)
48. Selegiline delays the onset of disability in de novo parkinsonian patients
49. Medical progress: Parkinson's disease (first of two parts)
50. The antioxidant N-acetylcysteine does not delay disease onset and death in a transgenic mouse model of amyotrophic lateral sclerosis
51. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
52. Trial of D-α-tocopherol in Huntington's disease
53. A controlled trial of idebenone in Huntington's disease
54. A randomized, double-blind, placebo-controlled, clinical trial of D-α-tocopherol acetate (vitamin E), as add-on therapy, for epilepsy in children
55. Pharmacology of lazaroids and brain energy metabolism: A review
56. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS)
57. Randomized, doubleblind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: A cooperative study in Europe, Australia, and New Zealand
58. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: A cooperative study in North America
59. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury: Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial
60. Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? a pragmatic analysis and theoretical considerations
61. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury
62. Mutations in the Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
63. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis
64. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis
65. Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca(2+)-loaded brain neurons
66. A fat little earner
67. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia
68. Sustained efficacy and safety of idebenone in the treatment of AIzheimer's disease: Update on a 2-year double-blind multicentre study
69. Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial
70. Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage
71. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment